Y-ECCO
27April2023

Y-ECCO Literature Review: Alice Moore

Alice Moore

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Louis E, Resche-Rigon M, Laharie D, et al; GETAID and the SPARE-Biocycle research group

Lancet Gastroenterol Hepatol 2023;8:215–27.


Alice Moore
© Alice Moore

Introduction

Therapeutic strategies for Crohn’s Disease have evolved over the past decade, with mounting evidence that achieving deep remission (defined as clinical, biochemical and endoscopic remission) is associated with better long-term outcomes [1, 2]. Combination therapy with infliximab and azathioprine has been shown to be superior to either infliximab or azathioprine monotherapy in achieving clinical remission and endoscopic healing in azathioprine-naive patients, thus supporting the paradigm of early disease management and the use of treatment combinations to increase treatment success [3]. Concerns regarding the implications of long-term combination therapy, such as infections and lymphoproliferative disorders, have provided the rationale for a formal clinical trial of treatment de-escalation.

The aim of this trial was to compare the relapse rate and the time spent in remission over 2 years between patients continuing combination therapy and those stopping infliximab or immunosuppressant therapy.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Volume 18, Issue 1, Y-ECCO

27April2023

Report on the 9th Y-ECCO Basic Science Workshop

Gabriele Dragoni, Y-ECCO Member


Gabriele Dragoni
© ECCO

After two consecutive virtual events, the Y-ECCO Basic Science Workshop was back with a face-to-face meeting, reaching its 9th edition on March 1, 2023, in Copenhagen.

This Workshop aims to involve young fellows in a fully comprehensive manner, giving them the opportunity to present relevant data that were submitted for the scientific programme and discuss their views with successful key opinion leaders in the field of Inflammatory Bowel Diseases (IBD), with special focus on basic and translational research. All sessions open with a hot topic presented by an invited senior specialist, followed by excellent presentations by selected young researchers. The secret of the constant success of this initiative is the friendly atmosphere, which allows participating Y-ECCO Members to increase their knowledge while also preparing for more challenging stages.

Posted in ECCO News, Committee News, Volume 18, Issue 1, Y-ECCO

27April2023

Y-ECCO Members’ Address

Mark Samaan, Y-ECCO Chair

Mark Samaan
© ECCO

Dear Y-ECCO Friends,

I do hope you all enjoyed the ECCO Congress in Copenhagen and made the most of the opportunity to “get physical” again for the first time in too long! I’m sure many will agree that, although virtual conferencing has its positives, much of what makes ECCO such a special organisation to be part of can only be fully realised in person. The fact that this year’s meeting was the first in-person ECCO Congress since before the pandemic only added to the sense of excitement, and the meeting’s content did not disappoint. As is often the case, contributions from Y-ECCO Members made up a sizeable proportion of the original research presented: 58 oral presentations were selected to be presented by Y-ECCO Members and a total of ten Y-ECCO Members were awarded prizes. This again underscores the essential role played by Y-ECCO within ECCO, as a new generation of IBD experts are ushered in. 

Posted in ECCO News, Committee News, Volume 18, Issue 1, Y-ECCO

19December2022

Y-ECCO Interview Corner: Krisztina Gecse

Robin Dart, Y-ECCO Member

Robin Dart
© ECCO

Krisztina Gecse is a consultant gastroenterologist at the Amsterdam University Medical Centre. She is well known to ECCO as a past Chair of ClinCom and is now at the forefront of the international push towards bowel ultrasound as President Elect of the International Bowel Ultrasound Group. I met with her to hear about her journey from Hungary to Amsterdam and how bowel ultrasound might just be your future….

Posted in ECCO News, Committee News, Y-ECCO, Volume 17, Issue 4

19December2022

Y-ECCO Literature Review: Mariam Mukhtar

Mariam Mukhtar

Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD)

Narula N, Wong ECL, Colombel J-F, et al.

Gut. 2022;71:1078–87.


Mariam Mukhtar
© Mariam Mukhtar

Introduction

Crohn’s Disease (CD) is a chronic condition resulting in continuous or episodic inflammation that manifests endoscopically with mucosal ulcerations, strictures, bleeding and/or fistulae. Clinical response and clinical remission have been identified as immediate and medium-term treatment targets, respectively. Endoscopic remission (ER) has been recognised as a long-term treatment target, one specifically associated with improved disease outcomes and reduced bowel damage and colectomy rates [1]. Recommendations from the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD) were recently updated. In this update, it was suggested that changes in therapy should be considered in patients who do not achieve ER [2].

In current clinical practice, endoscopy remains the gold standard for assessing mucosal healing [3]. Serial endoscopic examinations are therefore typically performed in cases of IBD, beginning at diagnosis and thereafter following changes in treatment, to document disease activity and extent and assess therapeutic response.

To measure and quantify mucosal inflammation objectively, different endoscopic indices have been implemented in clinical practice and clinical trials. Among these, the Simple Endoscopic Score for Crohn’s Disease (SES-CD) and the Crohn’s Disease Endoscopic Index of Severity (CDEIS) have been the most used metrics in clinical trials [1].

Compared to the CDEIS and other indices, the SES-CD offers the advantages of both simplicity and ease of use. Furthermore, the SES-CD has proven responsive to changes in disease activity, with good intra- and inter-observer agreement [4]. The SES-CD contains four parameters, each of which receives a uniform score between 0 and 3 in all disease locations. The SES-CD therefore assumes no differential weighting of each individual parameter according to its importance in predicting ER while on active therapy. In essence, the SES-CD score lacks prognostic potential.

In a prior study, it was observed that each of the SES-CD parameters has its own prognostic value in predicting treatment response and ER; further, this value is non-linear among disease locations [5].

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Y-ECCO, Volume 17, Issue 4

19December2022

Y-ECCO Literature Review: Konstantinos Sarras

Konstantinos Sarras

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the Immunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study

Chanchlani N, Lin S, Auth MK et al.

Aliment Pharmacol Ther. 2022;56:1250–63.


Konstantinos Sarras
© Konstantinos Sarras

Introduction

Anti-TNF monoclonal antibodies play an important role in the management of immune-mediated inflammatory diseases, including Inflammatory Bowel Disease [1]. However, anti-TNF failure is common [2]. Loss of response is usually associated with the development of anti-drug antibodies and low anti-TNF drug levels.

The aim of this study was to evaluate the relationship between immunogenicity to a patient’s first anti-TNF therapy and immunogenicity and drug persistence to the second anti-TNF therapy, irrespective of drug sequence.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Y-ECCO, Volume 17, Issue 4

19December2022

Y-ECCO Members’ Address

Charlotte Hedin, Y-ECCO Chair

Charlotte Hedin
© ECCO

Dear Y-ECCO Friends,

I hope you are all well and into the winter workflow. Many of us were representing IBD at the UEGW earlier in October, and many will have taken advantage of the excellent postgraduate course. Here in the ECCO Community we are excited soon to be launching The IBD Communication Toolbox. This is a series of podcasts where you can hear how IBD experts deal with questions that are commonly asked by patients. Firstly, the questions and topics addressed in the Communication Toolbox were selected in collaboration with patient representatives, ensuring that these are topics with high relevance for the IBD patients you meet in your practice.

Posted in ECCO News, Committee News, Y-ECCO, Volume 17, Issue 4

13October2022

Y-ECCO Interview Corner: Nicole Eichinger

Robin Dart, Y-ECCO Member

Robin Dart
© ECCO

ECCO is an ever-expanding organisation with educational activities which extend throughout the year. For this ECCO News I spoke with Nicole Eichinger, the Executive Director of ECCO, to find out a bit more about her and how the ECCO Team work behind the scenes to keep this vital organisation running as smoothly as it does.

Posted in ECCO News, Committee News, Y-ECCO, Volume 17, Issue 3

13October2022

Y-ECCO Literature Review: Chirag Patel

Chirag Patel

Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients

Hawthorne AB, Glatter J, Blackwell J, et al.

Aliment Pharmacol Ther. 2022;56:625–45.


Chirag Patel
© Chirag Patel

Introduction

In the United Kingdom (UK), approximately 500,000 people live with IBD, and in the coming decade it is anticipated that the prevalence of IBD will surpass 1% of the population [1]. In 2019, the third UK IBD Standards for adults and children were published following extensive patient and healthcare professional consultation [2]. The IBD Standards cover seven domains: service design and delivery; pre-diagnosis referral pathways; management of the newly diagnosed patient; flare management, including self-management and timely access to specialist advice; surgery including pre- and postoperative care; inpatient medical care; and ongoing long-term treatment and monitoring in both secondary and primary care.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Y-ECCO, Volume 17, Issue 3

13October2022

Y-ECCO Literature Review: Esha Sharma

Esha Sharma

Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study

Jayasooriya N, Blackwell J, Saxena S, et al.

Aliment Pharmacol Ther 2022;55:1330–41.


Esha Sharma
© Esha Sharma

Introduction

Inflammatory Bowel Disease (IBD) is a long-term condition of the gut which is known to impact the quality of life and social functioning of those affected due to the chronic nature of symptoms. These factors, along with communication across the gut–brain axis, cause many patients to suffer from mental health disorders such as anxiety and depression [1]. Previously, the magnitude of these comorbidities had not been established, but recent studies [1, 2] have found the prevalence to be high: a third of all patients and a half of those with an active IBD flare have been found to suffer from anxiety, while depression has been found to affect a quarter of patients and a third of those with active symptoms.

Furthermore, compared with controls, patients with IBD and mental health disorders show increased use of healthcare resources (both primary care visits and emergency secondary care visits) and increased use of antidepressant and anxiolytic medications [2]. While antidepressant medications are commonly used to treat anxiety and depression in IBD [3], understanding of how effectively these treatments are prescribed remains limited, and this is particularly true regarding the adequacy of duration of treatment in this cohort.

This population-based study was performed in the United Kingdom and used data from the primary care setting that was routinely collected electronically in general practices as part of the Clinical Practice Research Datalink (CPRD). The authors looked to review the antidepressant prescribing in primary care for those diagnosed with IBD. They focused on the rate of antidepressant treatment initiation following IBD diagnosis, the duration of antidepressant treatment according to international guidelines, potential risks of inadequate antidepressant treatment duration and general trends in antidepressant prescribing.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Y-ECCO, Volume 17, Issue 3